152 related articles for article (PubMed ID: 38354416)
21. CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110.
Domínguez JM; Pérez-Chacón G; Guillén MJ; Muñoz-Alonso MJ; Somovilla-Crespo B; Cibrián D; Acosta-Iborra B; Adrados M; Muñoz-Calleja C; Cuevas C; Sánchez-Madrid F; Avilés P; Zapata JM
J Hematol Oncol; 2020 Apr; 13(1):32. PubMed ID: 32264921
[TBL] [Abstract][Full Text] [Related]
22. Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) Payloads.
Puthenveetil S; Loganzo F; He H; Dirico K; Green M; Teske J; Musto S; Clark T; Rago B; Koehn F; Veneziale R; Falahaptisheh H; Han X; Barletta F; Lucas J; Subramanyam C; O'Donnell CJ; Tumey LN; Sapra P; Gerber HP; Ma D; Graziani EI
Bioconjug Chem; 2016 Aug; 27(8):1880-8. PubMed ID: 27412791
[TBL] [Abstract][Full Text] [Related]
23. Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping.
Khera E; Cilliers C; Smith MD; Ganno ML; Lai KC; Keating TA; Kopp A; Nessler I; Abu-Yousif AO; Thurber GM
Neoplasia; 2021 Feb; 23(2):210-221. PubMed ID: 33385970
[TBL] [Abstract][Full Text] [Related]
24. Pathophysiologic and Pharmacologic Considerations to Improve the Design and Application of Antibody-Drug Conjugates.
Boghaert ER; Cox MC; Vaidya KS
Cancer Res; 2022 May; 82(10):1858-1869. PubMed ID: 35298624
[TBL] [Abstract][Full Text] [Related]
25. Advances with antibody-drug conjugates in breast cancer treatment.
Abdus Subhan M; Torchilin VP
Eur J Pharm Biopharm; 2021 Dec; 169():241-255. PubMed ID: 34748933
[TBL] [Abstract][Full Text] [Related]
26. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
Tymon-Rosario J; Bonazzoli E; Bellone S; Manzano A; Pelligra S; Guglielmi A; Gnutti B; Nagarkatti N; Zeybek B; Manara P; Zammataro L; Harold J; Mauricio D; Buza N; Hui P; Altwerger G; Menderes G; Ratner E; Clark M; Andikyan V; Huang GS; Silasi DA; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2021 Nov; 163(2):334-341. PubMed ID: 34452746
[TBL] [Abstract][Full Text] [Related]
27. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
Harper J; Lloyd C; Dimasi N; Toader D; Marwood R; Lewis L; Bannister D; Jovanovic J; Fleming R; D'Hooge F; Mao S; Marrero AM; Korade M; Strout P; Xu L; Chen C; Wetzel L; Breen S; van Vlerken-Ysla L; Jalla S; Rebelatto M; Zhong H; Hurt EM; Hinrichs MJ; Huang K; Howard PW; Tice DA; Hollingsworth RE; Herbst R; Kamal A
Mol Cancer Ther; 2017 Aug; 16(8):1576-1587. PubMed ID: 28522587
[TBL] [Abstract][Full Text] [Related]
28. Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody-Drug Conjugates.
Matsuda Y; Seki T; Yamada K; Ooba Y; Takahashi K; Fujii T; Kawaguchi S; Narita T; Nakayama A; Kitahara Y; Mendelsohn BA; Okuzumi T
Mol Pharm; 2021 Nov; 18(11):4058-4066. PubMed ID: 34579528
[TBL] [Abstract][Full Text] [Related]
29. Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker.
Liubomirski Y; Tiram G; Scomparin A; Gnaim S; Das S; Gholap S; Ge L; Yeini E; Shelef O; Zauberman A; Berger N; Kalimi D; Toister-Achituv M; Schröter C; Dickgiesser S; Tonillo J; Shan M; Deutsch C; Sweeney-Lasch S; Shabat D; Satchi-Fainaro R
J Control Release; 2024 Mar; 367():148-157. PubMed ID: 38228272
[TBL] [Abstract][Full Text] [Related]
30. Antibody-Drug Conjugates Containing Payloads from Marine Origin.
Cheng-Sánchez I; Moya-Utrera F; Porras-Alcalá C; López-Romero JM; Sarabia F
Mar Drugs; 2022 Jul; 20(8):. PubMed ID: 36005497
[TBL] [Abstract][Full Text] [Related]
31. A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma.
Hoffmann RM; Crescioli S; Mele S; Sachouli E; Cheung A; Chui CK; Andriollo P; Jackson PJM; Lacy KE; Spicer JF; Thurston DE; Karagiannis SN
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32331483
[TBL] [Abstract][Full Text] [Related]
32. A Systems Pharmacology Model for Drug Delivery to Solid Tumors by Antibody-Drug Conjugates: Implications for Bystander Effects.
Burton JK; Bottino D; Secomb TW
AAPS J; 2019 Dec; 22(1):12. PubMed ID: 31828446
[TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
[TBL] [Abstract][Full Text] [Related]
34. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
35. Intratumoral Payload Concentration Correlates with the Activity of Antibody-Drug Conjugates.
Zhang D; Yu SF; Khojasteh SC; Ma Y; Pillow TH; Sadowsky JD; Su D; Kozak KR; Xu K; Polson AG; Dragovich PS; Hop CECA
Mol Cancer Ther; 2018 Mar; 17(3):677-685. PubMed ID: 29348271
[TBL] [Abstract][Full Text] [Related]
36. Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect.
Yurkovetskiy AV; Bodyak ND; Yin M; Thomas JD; Clardy SM; Conlon PR; Stevenson CA; Uttard A; Qin L; Gumerov DR; Ter-Ovanesyan E; Bu C; Johnson AJ; Gurijala VR; McGillicuddy D; DeVit MJ; Poling LL; Protopopova M; Xu L; Zhang Q; Park PU; Bergstrom DA; Lowinger TB
Mol Cancer Ther; 2021 May; 20(5):885-895. PubMed ID: 33722857
[TBL] [Abstract][Full Text] [Related]
37. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
[TBL] [Abstract][Full Text] [Related]
38. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
[TBL] [Abstract][Full Text] [Related]
39. Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates.
Petersen ME; Brant MG; Lasalle M; Das S; Duan R; Wong J; Ding T; Wu KJ; Siddappa D; Fang C; Zhang W; Wu AML; Hirkala-Schaefer T; Garnett GAE; Fung V; Yang L; Hernandez Rojas A; Lawn SO; Barnscher SD; Rich JR; Colombo R
Mol Cancer Ther; 2024 May; 23(5):606-618. PubMed ID: 38354417
[TBL] [Abstract][Full Text] [Related]
40. Modeling to capture bystander-killing effect by released payload in target positive tumor cells.
Byun JH; Jung IH
BMC Cancer; 2019 Mar; 19(1):194. PubMed ID: 30832603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
